Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN™), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors
- 24 March 2009
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Chemotherapy and Pharmacology
- Vol. 64 (6), 1165-1172
- https://doi.org/10.1007/s00280-009-0979-8
Abstract
To evaluate safety and tolerability of cediranib, a highly potent and selective vascular endothelial growth factor signaling inhibitor, in Japanese patients with advanced solid tumors refractory to standard therapies.Keywords
This publication has 26 references indexed in Scilit:
- Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinomaAmerican Journal of Health-System Pharmacy, 2008
- Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing programPediatric Blood & Cancer, 2008
- Tumoral Angiogenesis: Review of the LiteratureCancer Investigation, 2008
- Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenograftsMolecular Cancer Therapeutics, 2007
- Phase I Clinical Study of AZD2171, an Oral Vascular Endothelial Growth Factor Signaling Inhibitor, in Patients With Advanced Solid TumorsJournal of Clinical Oncology, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Vascular Endothelial Growth Factor (VEGF) PathwayJournal of Thoracic Oncology, 2006
- Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and AngiogenesisJournal of Clinical Oncology, 2005
- The biology of VEGF and its receptorsNature Medicine, 2003
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000